Compound is being evaluated in cancer and chronic viral indications.
Laureate Pharma entered a cGMP contract manufacturing agreement with Tolerx related to the latter’s candidate for cancer and chronic viral diseases. The humanized anti-GITR antibody known as TRX518 is in preclinical development.
TRX518 is thought to circumvent immune system tolerance by inhibiting the suppressive activity of T regulatory cells and extending the survival of T effector cells, thereby enhancing responses to tumor and viral antigens.
“Laureate Pharma has a proven track record in biopharmaceutical manufacturing, including capabilities in both clinical- and commercial-grade materials,” according to Douglas J. Ringler, VMD, president and CEO of Tolerx. “This agreement enables us to operationally leverage Laureate’s expertise and infrastructure while we seek to establish new treatment paradigms in the immunology space.”
